Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 285

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

Open access
Lamberts, Laetitia E., Koch, Maximillian, de Jong, Johannes S., Adams, Arthur L.L., Glatz, Jürgen, Kranendonk, Mariëtte E.G., Terwisscha van Scheltinga, Anton G.T., Jansen, Liesbeth, de Vries, Jakob, Lub-de Hooge, Marjolijn N., Schröder, Carolien P., Jorritsma-Smit, Annelies, Linssen, Matthijs D., de Boer, Esther, van der Vegt, Bert, Nagengast, Wouter B., Elias, Sjoerd G., Oliveira, Sabrina, Witkamp, Arjen J., Mali, Willem P.Th.M., Van der Wall, Elsken, van Diest, Paul J., de Vries, Elisabeth G.E., Ntziachristos, Vasilis, van Dam, Gooitzen M.·2017·Clinical Cancer Research

Abstract

Purpose: To provide proof of principle of safety, breast tumor–specific uptake, and positive tumor margin assessment of the systemically administered near-infrared fluorescent tracer bevacizumab–IRDye800CW targeting VEGF-A in patients with breast cancer. Experimental Design: Twenty patients with primary invasive breast cancer eligible for primary surgery received 4.5 mg bevacizumab–IRDye800CW as intravenous bolus injection. Safety aspects were assessed as well as tracer uptake and tumor delineation during surgery and ex vivo in surgical specimens using an optical imaging system. Ex vivo multiplexed histopathology analyses were performed for evaluation of biodistribution of tracer uptake and coregistration of tumor tissue and healthy tissue. Results: None of the patients experienced adverse events. Tracer levels in primary tumor tissue were higher compared with those in the tumor margin (P < 0.05) and healthy tissue (P < 0.0001). VEGF-A tumor levels also correlated with tracer levels (r = 0.63, P < 0.0002). All but one tumor showed specific tracer uptake. Two of 20 surgically excised lumps contained microscopic positive margins detected ex vivo by fluorescent macro- and microscopy and confirmed at the cellular level. Conclusions: Our study shows that systemic administration of the bevacizumab–IRDye800CW tracer is safe for breast cancer guidance and confirms tumor and tumor margin uptake as evaluated by a systematic validation methodology. The findings are a step toward a phase II dose-finding study aimed at in vivo margin assessment and point to a novel drug assessment tool that provides a detailed picture of drug distribution in the tumor tissue. Clin Cancer Res; 23(11); 2730–41. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-0437

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 285

Metadata

Authors
Lamberts, L. E., Koch, M., de Jong, J. S., Adams, A. L. L., Glatz, J., Kranendonk, M. E. G., Terwisscha van Scheltinga, A. G. T., Jansen, L., de Vries, J., Lub-de Hooge, M. N., Schröder, C. P., Jorritsma-Smit, A., Linssen, M. D., de Boer, E., van der Vegt, B., Nagengast, W. B., Elias, S. G., Oliveira, S., Witkamp, A. J., Mali, W. P. T. M., Van der Wall, E., van Diest, P. J., de Vries, E. G. E., Ntziachristos, V., & van Dam, G. M.
Venue
Clinical Cancer Research
Published
2017-05-31
Volume
23
Issue
11
Pages
2730-2741
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2554295594
Cited by
285
References
35
FWCI
20.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0437
The paper
Lamberts, L. E., Koch, M., de Jong, J. S., Adams, A. L. L., Glatz, J., Kranendonk, M. E. G., Terwisscha van Scheltinga, A. G. T., Jansen, L., de Vries, J., Lub-de Hooge, M. N., Schröder, C. P., Jorritsma-Smit, A., Linssen, M. D., de Boer, E., van der Vegt, B., Nagengast, W. B., Elias, S. G., Oliveira, S., Witkamp, A. J., . . . van Dam, G. M. (2017). Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0437

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.